By Canadian Press

BioNTech CEO confident vaccine will work on UK variant

Dec 22, 2020 | 2:22 AM

BERLIN — German pharmaceutical company BioNTech is confident that its coronavirus vaccine works against the new UK variant, but further studies are need to be completely sure, its chief executive said Tuesday.

The variant, detected mainly in London and the southeast of England in recent weeks, has sparked concern worldwide because of signs that it may spread more easily. While there is no indication it causes more serious illness, numerous countries in Europe and beyond have restricted travel from the UK as a result.

“We don’t know at the moment if our vaccine is also able to provide protection against this new variant,” Ugur Sahin told a news conference the day after the vaccine was approved for use in the European Union. “But scientifically, it is highly likely that the immune response by this vaccine also can deal with the new virus variants.”

Sahin said that the proteins on the UK variant are 99% the same as on the prevailing strains, and therefore BioNTech has “scientific confidence” that its vaccine will be effective.

“But we will know it only if the experiment is done and we will need about two weeks from now to get the data,” he said. “The likelihood that our vaccine works … is relatively high.”

Seasonal Sorrow

How Do You Get Through The Holidays When You're Grieving?

Nov 01, 2024

Upcoming Events at Oliver's

Grief & Loss and Estate Planning Seminars

Oct 02, 2024

Local History

Oliver's Funeral Home - 109 years of Service

Sep 04, 2024

Should the vaccine need to be adjusted for the new variant the company could do so in about 6 weeks, said Ugur, though regulators might have to approve the changes before the shots can be used.

BioNTech’s vaccine, developed together with U.S. pharmaceutical company Pfizer, is authorized for use in more than 45 countries including Britain, the United States and the EU.

___

Follow AP’s pandemic coverage at http://apnews.com/VirusOutbreak and https://apnews.com/UnderstandingtheOutbreak

The Associated Press